SCORE study report #11

Incidences of neovascular events in eyes with retinal vein occlusion

Clement K. Chan, Michael S. Ip, Paul C. Vanveldhuisen, Neal L. Oden, Ingrid Scott, Michael J. Tolentino, Barbara A. Blodi

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as "nonperfusion"), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events. Design: Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). Participants: At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. Intervention: Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone. Main Outcome Measures: Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion. Results: The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with <5.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at <5.5 disc areas. Conclusions: In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article.

Original languageEnglish (US)
Pages (from-to)1364-1372
Number of pages9
JournalOphthalmology
Volume118
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Retinal Vein Occlusion
Retinal Vein
Incidence
Neovascular Glaucoma
Triamcinolone
Light Coagulation
Iris
Observation
Retinal Neovascularization
Vitreous Hemorrhage
Disclosure

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Chan, C. K., Ip, M. S., Vanveldhuisen, P. C., Oden, N. L., Scott, I., Tolentino, M. J., & Blodi, B. A. (2011). SCORE study report #11: Incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology, 118(7), 1364-1372. https://doi.org/10.1016/j.ophtha.2010.11.020
Chan, Clement K. ; Ip, Michael S. ; Vanveldhuisen, Paul C. ; Oden, Neal L. ; Scott, Ingrid ; Tolentino, Michael J. ; Blodi, Barbara A. / SCORE study report #11 : Incidences of neovascular events in eyes with retinal vein occlusion. In: Ophthalmology. 2011 ; Vol. 118, No. 7. pp. 1364-1372.
@article{359f0bd58c6140328759be77febe2c2b,
title = "SCORE study report #11: Incidences of neovascular events in eyes with retinal vein occlusion",
abstract = "Purpose: To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as {"}nonperfusion{"}), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events. Design: Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). Participants: At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. Intervention: Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone. Main Outcome Measures: Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion. Results: The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5{\%} and 2.4{\%} for NVI or NVG; 8.8{\%} and 7.6{\%} for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6{\%} of eyes with <5.5 disc areas of nonperfusion versus 4.0{\%} of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6{\%} versus 2.4{\%} developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at <5.5 disc areas. Conclusions: In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article.",
author = "Chan, {Clement K.} and Ip, {Michael S.} and Vanveldhuisen, {Paul C.} and Oden, {Neal L.} and Ingrid Scott and Tolentino, {Michael J.} and Blodi, {Barbara A.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.ophtha.2010.11.020",
language = "English (US)",
volume = "118",
pages = "1364--1372",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "7",

}

Chan, CK, Ip, MS, Vanveldhuisen, PC, Oden, NL, Scott, I, Tolentino, MJ & Blodi, BA 2011, 'SCORE study report #11: Incidences of neovascular events in eyes with retinal vein occlusion', Ophthalmology, vol. 118, no. 7, pp. 1364-1372. https://doi.org/10.1016/j.ophtha.2010.11.020

SCORE study report #11 : Incidences of neovascular events in eyes with retinal vein occlusion. / Chan, Clement K.; Ip, Michael S.; Vanveldhuisen, Paul C.; Oden, Neal L.; Scott, Ingrid; Tolentino, Michael J.; Blodi, Barbara A.

In: Ophthalmology, Vol. 118, No. 7, 01.07.2011, p. 1364-1372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - SCORE study report #11

T2 - Incidences of neovascular events in eyes with retinal vein occlusion

AU - Chan, Clement K.

AU - Ip, Michael S.

AU - Vanveldhuisen, Paul C.

AU - Oden, Neal L.

AU - Scott, Ingrid

AU - Tolentino, Michael J.

AU - Blodi, Barbara A.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Purpose: To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as "nonperfusion"), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events. Design: Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). Participants: At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. Intervention: Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone. Main Outcome Measures: Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion. Results: The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with <5.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at <5.5 disc areas. Conclusions: In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article.

AB - Purpose: To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as "nonperfusion"), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events. Design: Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). Participants: At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. Intervention: Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone. Main Outcome Measures: Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion. Results: The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with <5.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at <5.5 disc areas. Conclusions: In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=79959946982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959946982&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.11.020

DO - 10.1016/j.ophtha.2010.11.020

M3 - Article

VL - 118

SP - 1364

EP - 1372

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 7

ER -